COR659(COR659) - 药物靶点：GABAB receptor_在研适应症：酗酒_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点

GABAB receptor

作用机制

GABAB receptor 正变构调节剂(γ-氨基丁酸B受体正变构调节剂)

治疗领域

其他疾病

在研适应症

酗酒

非在研适应症-

原研机构

Consiglio Nazionale delle Ricerche

在研机构

Consiglio Nazionale delle Ricerche

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 COR659 相关的临床结果

登录后查看更多信息

100 项与 COR659 相关的转化医学

登录后查看更多信息

100 项与 COR659 相关的专利（医药）

登录后查看更多信息

1

项与 COR659 相关的文献（医药）

2024-03-16·Alcohol and Alcoholism

Positive allosteric modulators of the GABAB receptor: a new class of ligands with therapeutic potential for alcohol use disorder

Review

作者: Colombo, Giancarlo

AbstractBackgroundPositive allosteric modulators (PAMs) of the GABAB receptor constitute a new class of GABAB-receptor ligands. GABAB PAMs reproduce several pharmacological effects of the orthosteric GABAB receptor agonist, baclofen, although displaying a better safety profile.AimsThis paper reviews the reducing or, frequently, even suppressing effects of all GABAB PAMs tested to date on multiple alcohol-related behaviours in laboratory rodents exposed to validated experimental models of human alcohol use disorder.ResultsAcute or repeated treatment with CGP7930, GS39783, BHF177, rac-BHFF, ADX71441, CMPPE, COR659, ASP8062, KK-92A, and ORM-27669 reduced excessive alcohol drinking, relapse- and binge-like drinking, operant alcohol self-administration, reinstatement of alcohol seeking, and alcohol-induced conditioned place preference in rats and mice.ConclusionsThese effects closely mirrored those of baclofen; notably, they were associated to remarkably lower levels of tolerance and toxicity. The recent transition of ASP8062 to clinical testing will soon prove whether these highly consistent preclinical data translate to AUD patients.

100 项与 COR659 相关的药物交易

登录后查看更多信息